Prognostic Impact of Tumor Solid Components in Stereotactic Body Radiotherapy for Clinical Stage Tis– 1N0M0 Lung Cancer
Thoracic Cancer · 2025
DOI: 10.1111/1759-7714.70110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Junki Fukuda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. Hauptthemen laut MEDLINE: Radiosurgery, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Purpose
This study aimed to assess the potential of prognostic factors including consolidation tumor ratio (CTR) on treatment outcomes in patients with clinical stage 0–IA non‐small cell lung cancer (NSCLC) undergoing stereotactic body radiotherapy (SBRT).
Methods
The analysis included data of 63 patients with 67 lesions of clinical stage 0–IA NSCLC treated with SBRT. According to the Union for International Cancer Control 8th edition, the following tumor stages were observed: Tis, 3; T1mi, 2; T1a, 11; T1b, 29; and T1c, 22. The prescribed dose was 48 (range, 42–52) Gy in four fractions.
Results
The median follow‐up was 29.3 (range: 2.4–120.5) months. The five‐year local control (LC), overall survival, and progression‐free survival (PFS) rates were 89.4%, 60.3%, and 40.5%, respectively. Squamous cell carcinoma (Sq) and D max < 125 Gy BED10 for planning target volume (PTV) were associated with a worse LC ( p = 0.001 and 0.017, respectively). Patients with Sq, T1b–c, CTR > 0.25, PTV ≥ 30 cm 3 tumors were associated with worse PFS than those with non‐Sq, ≤ cT1a, CTR ≤ 0.25, PTV < 30 cm 3 tumors ( p = 0.049, 0.004, 0.038, and 0.004, respectively). No recurrences, metastases, or deaths were found in patients with CTR ≤ 0.25 ( n = 5).
Conclusion
In patients with stage 0–IA lung cancer treated with SBRT, tumors classified as ≤ T1a showed a better PFS than T1b–c. NSCLC with a low CTR of ≤ 0.25 seemed to have a low risk of recurrence after SBRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
- Department of Radiology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
- Department of Radiology, Wakayama Medical University, Wakayama, Japan.
ORCID-Profile: Hiroshi Doi, Yukinori Matsuo
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Fukuda, J., Doi, H., Kono, A., Inagaki, T., Hamazawa, N. I., Imamura, S. T., Uehara, T., Inada, M., Nakamatsu, K., Hosono, M., Ishii, K., & Matsuo, Y. (2025). Prognostic Impact of Tumor Solid Components in Stereotactic Body Radiotherapy for Clinical Stage Tis– 1N0M0 Lung Cancer. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70110
Vancouver
Fukuda J, Doi H, Kono A, Inagaki T, Hamazawa NI, Imamura ST, et al. Prognostic Impact of Tumor Solid Components in Stereotactic Body Radiotherapy for Clinical Stage Tis– 1N0M0 Lung Cancer. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70110
BibTeX
@article{Fukuda2025,
author = {Fukuda, Junki and Doi, Hiroshi and Kono, Atsushi and Inagaki, Takaya and Hamazawa, Naoko Ishida and Imamura, Saori Tatsuno and Uehara, Takuya and Inada, Masahiro and Nakamatsu, Kiyoshi and Hosono, Makoto and Ishii, Kazunari and Matsuo, Yukinori},
title = {Prognostic Impact of Tumor Solid Components in Stereotactic Body Radiotherapy for Clinical Stage Tis– 1N0M0 Lung Cancer},
journal = {Thoracic Cancer},
year = {2025},
doi = {10.1111/1759-7714.70110}
}
EUVIMED